December 11, 2017.
Prostate cancer is one of the most common in France. If it is treated better and better, certain forms, particularly aggressive, lower the chances of survival of this disease. In Lille, a Ukrainian researcher is currently working on the development of an effective treatment against these cancers.
The ARC Foundation funds a research project against prostate cancer
At the cell physiology laboratory at the University of Lille, a scientific study against prostate cancer is progressing by leaps and bounds. Led by Ukrainian researcher V’yacheslav Lehen’Kyi, this study has just received funding from the ARC Foundation against cancer, and could lead to a clinical trial within two years.
The project of this researcher lies in a targeted therapy for aggressive prostate cancers and is characterized in the form ofan antibody, which would be able to bind to the channel responsible for calcium absorption (TRPV6 channel) implicated in this form of cancer.
Each year, nearly 9,000 men die of prostate cancer
” This channel is present in prostate tumor cells, but not in healthy cells. And we observed that it was particularly present in aggressive cancer cells. The monoclonal antibody will act on the channel to kill cancer cells », Explains the researcher in a press release.
Prostate cancer is the most common cancer in men today. It occurs most often around the age of 70. According to figures from the National Cancer Institute, this form of the disease affects nearly 60,000 people per year but this figure is decreasing every year. In 2015, nearly 9,000 deaths linked to this cancer were recorded.
Gaelle Latour
Read also A virus responsible for prostate cancer?
